$15.85
Personalis, Inc.
Personalis, Inc. in the Healthcare sector is trading at $15.85 with a market capitalization of $1.7B. Wall Street consensus targets $15.17 (3 analysts), implying a -4.3% move over the next 12 months. The stock is currently 16% below its 52-week high of $18.89, remaining 46.2% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 25 is oversold, raising the odds of a near-term bounce. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $22.36Mβ | $15.47Mβ | $17.34Mβ | $14.49Mβ | $17.20M |
| Gross Profit | $4.74Mβ | $281,000β | $1.90Mβ | $1.91Mβ | $4.76M |
| Operating Income | -$33.59Mβ | -$32.16Mβ | -$25.27Mβ | -$23.29Mβ | -$21.80M |
| Net Income | -$31.68Mβ | -$30.03Mβ | -$23.81Mβ | -$21.65Mβ | -$20.06M |
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), ...